Horizon joins predictive biomarker consortium; PerkinElmer buys VisEn; Sigma-Aldrich developing new biomarker tech;

> Horizon Discovery has joined a newly-formed consortium that has set out to discover a new generation of predictive cancer biomarkers. Report

> PerkinElmer has acquired VisEn Medical, an in vivo molecular imaging technology company based in Bedford, Massachusetts, for an undisclosed sum. PerkinElmer release

> Sigma-Aldrich has forged an agreement with the National Heart, Lung, and Blood Institute and Boston University to develop new methods to measure several potential biomarkers of atherosclerotic cardiovascular disease using plasma samples from the NHLBI's Framingham Heart Study. Sigma-Aldrich release

> Researchers at UCLA have now developed a microfluidic image cytometry (MIC) platform that can measure cell-signaling pathways in brain tumor samples at the single-cell level. The new technology combines the advantages of microfluidics and microscopy-based cell imaging. Release

> Israel's Micromedic Technologies, which develops biomarkers for cancer and diabetes, has raised NIS 11.8 million from a secondary offering. Report

> Life Technologies and UC San Diego's Moores Cancer Center are teaming up to identify prognostic biomarkers on the progression of chronic lymphocytic leukemia. Life Technologies release

> Almac is touting its biomarkers for biopharma program, helping developers identify a biomarker strategy to help them improve the odds of success during clinical development. Almac release

> Millennium reports that it has discovered potential biomarkers of Velcade activity in patients with relapsed mantle cell lymphoma. Millennium release

> St. Louis-based Mediomics won a $460,000 grant from the National Institute of General Medical Sciences to develop its homogenous PINCER protein assay. Mediomics release